An ALLG/TROG Prospective Multicentre Study of Involved-Field Radiotherapy with Transplantation for Patients with Hodgkin’s Disease and non-Hodgkin’s Lymphoma

Treatment options for patients with relapsed lymphoma include standard-dose chemotherapy, radiotherapy or high-dose chemotherapy and peripheral blood stem cell transplantation. It has been found that if lymphoma recurs after transplantation it often does so in sites involved prior to transplantation. Radiotherapy can prevent some of these relapses, and may improve the overall results of transplantation. Radiotherapy is often given only to bulky sites (i.e. more than 5-10 cm in size) of lymphoma following transplantation, but the optimal dose and area of radiotherapy is not known. It is possible that treating all the areas of lymphoma (including non-bulky areas) may be more effective. In this research study, radiotherapy was given to all the areas known to be affected by lymphoma (other than bone marrow) with the aims of assessing the ability of radiotherapy to reduce the risk of relapse following transplantation, and carefully evaluating the side effects of adding radiotherapy to transplantation.

Primary Sponsor

Australasian Leukaemia & Lymphoma Group (ALLG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

45

Trial Chairperson

A/Prof Andrew Wirth
Peter MacCallum Cancer Centre
VIC

Related Post

17 September, 2026

Meet the TROG Quality Assurance team

TROG UPDATES: 17 September 2026 Our Quality Assurance team

17 September, 2026

TROG trial of new lung cancer radiation therapy approach opens

LATEST NEWS: 17 September 2026 The first Australian site